CEREVEL THERAPEUTICS HOLDINGS, INC. Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.12 USD | -0.05% |
|
+0.76% | -0.54% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
| Apr. 18 | Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -456M | Net income 2025 * | -551M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 709M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-16.9
x | P/E ratio 2025 * |
-15
x | Employees | 334 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cerevel Therapeutics Holdings, Inc.
More recommendations
More press releases
| 1 day | +1.30% | ||
| 1 week | +0.31% | ||
| Current month | -0.31% | ||
| 1 month | -0.99% | ||
| 3 months | -0.35% | ||
| 6 months | +85.56% | ||
| Current year | -0.61% |
1 week
41.19
42.21
1 month
41.1942.60
Current year
40.6643.59
1 year
19.5943.59
3 years
12.0146.16
5 years
9.0046.16
10 years
9.0046.16
| Managers | Title | Age | Since |
|---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
| Director of Finance/CFO | 43 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19-05-31 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 18-08-31 |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 42.19 | +0.12% | 45 805 |
| 24-04-18 | 42.14 | +1.30% | 1,282,830 |
| 24-04-17 | 41.6 | +0.70% | 838,023 |
| 24-04-16 | 41.31 | -0.94% | 1,439,526 |
| 24-04-15 | 41.7 | -0.36% | 1,333,538 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
42.14
USD
Average target price
44.78
USD
Spread / Average Target
+6.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.61% | 7.65B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.02% | 21.66B | |
| -18.35% | 20.77B | |
| -7.68% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- CERE Stock
